Arthur Higgins named to Resverlogix board

Resverlogix (TSX:RVX) has appointed Arthur Higgins, CEO of Bayer HealthCare and chairman of the Bayer HealthCare executive committee, to the board, effective Feb. 1.

“Arthur Higgins’ global leadership experience and exposure to numerous healthcare markets are just a few of the reasons that he is a valued addition to the (Resverlogix) board,” CEO Donald McCaffrey said in a statement.

“As we progress through our Phase 2 clinical trials, we welcome Mr. Higgins’ perspective as a strategist and R&D specialist,” he added.

Mr. Higgins joined Bayer in 2004, after senior executive roles with Abbott Labs and Enzon Pharmaceuticals. He played a key role in Bayer’s 17 billion-euro acquisition of the German pharma company, Schering AG, in 2006.

Mr. Higgins represents Bayer in the executive committee of the Pharmaceutical Research and Manufacturers of America, and is also a member of the Council of the International Federation of Pharmaceutical Manufacturers and Associations. From May 2007 until Dec. 2009, he was president of the European Federation of Pharmaceutical Industries and Associations.